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Abstract
Background: This study used a large-scale cancer database in determination of prognostic factors
for the survival of lung cancer subjects in Taiwan.
Methods: Total of 24,910 subjects diagnosed with lung cancer was analysed. Survival estimates by
Kaplan-Meier methods. Cox proportional-hazards model estimated the death risk (hazard ratio
(HR)) for various prognostic factors.
Results: The prognostic indicators associated with a higher risk of lung cancer deaths are male
gender (males versus females; HR = 1.07, 95% confidence intervals (CI): 1.03–1.11), males
diagnosed in later periods (shown in 1991–1994 versus 1987–1990; HR = 1.13), older age at
diagnosis, large cell carcinoma (LCC)/small cell carcinoma (SCC), and supportive care therapy over
chemotherapy. The overall 5-year survival rate for lung cancer death was significantly poorer for
males (21.3%) than females (23.6%). Subjects with squamous cell carcinoma (SQCC) and treatment
by surgical resection alone had better prognosis. We find surgical resections to markedly increase
5-year survival rate from LCC, decreased risk of death from LCC, and no improved survival from
SCC.
Conclusion: Gender and clinical characteristics (i.e. diagnostic period, diagnostic age, histological
type and treatment modality) play important roles in determining lung cancer survival.
Background
Lung cancer is the leading cause of cancer deaths world-
wide with geographic and demographic distinctions. Age-
standardized incidence rate adjusted by world population
(ASRW) for lung cancer is 35.5 per 100,000 males and
12.1 per 100,000 females in 2002, in the world [1]. The
Published: 7 November 2008
BMC Cancer 2008, 8:324 doi:10.1186/1471-2407-8-324
Received: 6 May 2008
Accepted: 7 November 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/324
© 2008 Chiang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:324 http://www.biomedcentral.com/1471-2407/8/324
Page 2 of 8
(page number not for citation purposes)
highest ASRW for males is in central-Eastern Europe and
Northern America with 60 per 100,000, for females is in
Northern America with 35.6 per 100,000, and most differ-
ences between genders in central-Eastern Europe (M: F =
7.55: 1). Lung cancer is a highly malignant neoplasm with
poor prognosis when diagnosed at an advanced stage, and
prognostication is crucial for clinicians. Many factors may
influence lung cancer survival, including gender [2,3],
diagnostic age [4,5], histological type [6,7], and treatment
modality [8-10].
For the Taiwanese in 2002, age-adjusted incidence rate of
lung cancer was 38.38 per 100,000 males and 19.62 per
100,000 females (M: F = 1.96:1), ranked the second most
prevalent cancer in males and fifth in females. Similarly,
the age-adjusted mortality rate was 37.75 and 17.85 per
100,000 for males and females, respectively (M: F = 2.11:
1) [11]. Gender has not yet been analyzed as a predictor
of survival rate, despite lung cancer incidence and mortal-
ity rates showing a male predominance and prognostic
factors have been controversial. Present study determines,
by gender, the prognostic characteristics of lung cancer
subjects in Taiwan. We used a large-scale cancer database
from Taiwan Cancer Registry (TCR) to disclose prognostic
differences in survival between genders as opposed to a
short-term analysis on local hospital data.
Methods
Study data
Two systems enlisted. The Taiwan Cancer Registry is a
large population-based database established by the
National Department of Health provided information on
lung cancer subjects (ICD-9 code 162). All discharge notes
and data of patient's primary diagnosis of cancer were
reviewed by registry-trained personnel in every hospital.
This practice remained consistent and unaltered up to this
date. Cancer cases from hospitals of at least 50 beds have
notified and forwarded to National Department of Health
on a compulsory basis. Almost every such hospital partic-
ipated in this schema (total more than 185 hospitals).
Cancer was diagnosed both clinically and histopathologi-
cally, and data checked for accuracy and completeness at
the National Department of Health, only validated data
stored. Proportion of lung cancer cases histo-pathologi-
cally diagnosed in the TCR database is greater than 80%
[11]. The other system, the mortality database, received
standardized death certificates, made mandatory to physi-
cians by the National Department of Health. The vital sta-
tistics published by the National Health Department is
very complete, with a physician confirmation rate of 99%.
Our study population (N = 24,910) comprising of the
diagnosed lung cancer subjects from 1987 to 1994,
recruited via the TCR system and followed-up, matched
correspondingly into the mortality database. Subjects' sur-
vival days post-diagnosis were ascertained by an active
validation of their vital status until December 31, 2000.
Descriptive prognostic features
Data accrued in this study include gender, resident area,
diagnostic age, histological type at diagnosis, course of
treatment, date, and cause of death. Subjects were
grouped into three ethnicities, according to their area of
residence where the community exceeds 80% of the area's
population, the aboriginal Taiwanese, the Hakka, and
Hokkien [12]. Histological types defined by ICD-O cod-
ing system. Lung cancer subjects were grouped into path-
ological (76%), clinical (10%) and imaging (14%)
diagnoses [11]. Pathological diagnosis pertained to sev-
eral histological subtypes, such as carcinoma not other-
wise specified (NOS: M8000-M8004, M8010-M8011,
M8032-M8034), squamous cell carcinoma (SQCC:
M8050-8076), adenocarcinoma (M8140, 8211,
8230–8231, 8250–8260, 8323, 8550–8560, 8570–8572),
small cell carcinoma (SCC: M8040-8045), large cell carci-
noma (LCC: M8012-8031, M8310), and other carcino-
mas [13]. The treatment modalities examined were
surgical resection alone, radiation therapy (RT) alone,
chemotherapy (CT) alone, supportive care therapy (ST)
alone (prescribing morphine for cancer pain, oxygen for
symptomatic care of chronic obstructive pulmonary dis-
ease (COPD), antidepressants in treatment of depression
within hospital care), and other complex therapy (immu-
notherapy, hormonal therapy, and traditional Chinese
herbal medicine therapy), and unknown therapy [11].
Statistical analysis
Lung cancer death (after eliminated other competing
causes of death) was treated as two distinct outcomes for
the purpose of this study. In our lung cancer survival anal-
ysis, deaths fulfilling the ICD-162 criteria were classified
as deaths from lung cancer, whereas those who died from
other causes or still alive became censored observations.
Using log-rank test, the gender curves differed signifi-
cantly for lung cancer death, so the subjects were segre-
gated into male and female groups. Frequency
distributions on demographic, clinical and therapy char-
acteristics on gender were compared by the chi-square
test. Survival days after diagnosis were estimated by Kap-
lan-Meier and 5-year survival rates (absolute survivals)
presented. For each gender, we conducted relative survival
analysis (defined as observed survival divided by expected
survival, adjusting for expected mortality that the cohort
would have from all causes of death [14]). Survival rates
differed significantly for each clinical factor outcome by
gender with the log-rank test. After log-log survival plots
were used to verify the proportion hazard assumptions for
each predictor, the Cox proportional-hazards model was
applied to estimate their contributions. The adjusted mul-
tiple variables of prognostic factors (diagnostic period,BMC Cancer 2008, 8:324 http://www.biomedcentral.com/1471-2407/8/324
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diagnostic age, resident area, histological type diagnosis,
therapeutic choice) were used in assessing the hazard ratio
(HR) of their relationships, based on gender survival. All
analyses used SAS version 8.2 statistical software (SAS
Institute, Inc., Cary, NC, USA).
Results
Distribution of prognostic characteristics by gender (Table 
1)
Total of 24,910 subjects (72% males and 28% females)
were analysed during the period 1987–1994. Results
showed that each characteristic to be strongly associated
with gender. Males were diagnosed at a significantly older
age than females. Particularly, in both genders, the pro-
portion of subjects was significantly higher in 1991–1994
than 1987–1990. For the proportion of diagnostic age,
females were predominantly higher than males in
younger age groups (<= 59 years). Males were significantly
more likely to present with SQCC than other types,
whereas females were significantly more likely to present
with adenocarcinoma than other types. With regards to
the therapeutic choice, except for unknown therapy, ST
was the most frequented treatment modality, followed by
RT, surgical resection, and CT in both genders. Females
were more likely to choose ST and unknown therapy ver-
sus a significantly higher proportion of males treated with
RT and CT therapy.
Table 1: Characteristics of lung cancer subjects at time of 
diagnosis by gender in 1987–1994
Males
(N = 18,056)
Females
(N = 6854)
Characteristics N (%)a N (%)a p Value
Mean age (years) ± S.D. 64.8 ± 9.9 62.2 ± 14.5 < 0.0001
Period of diagnosis (years)
1987–1990 7455 (41) 2690 (39) 0.003
1991–1994 10601 (59) 4164 (61)
Diagnostic age (yrs)
<= 39 418 (2) 382 (6) < 0.0001
40–49 855 (5) 730 (11)
50–59 3069 (17) 1409 (21)
60–69 7364 (41) 2137 (31)
>= 70 6320 (35) 2196 (32)
Resident area
Aboriginal community 410 (2) 128 (2) 0.0060
Hakka community 1462 (8) 491 (7)
Hokkien community 16184 (90) 6235 (91)
Histological type
SQCC 5855 (32) 1003 (15) < 0.0001
Adenocarcinoma 4880 (27) 3156 (46)
SCC 2005 (11) 276 (4)
LCC 326 (2) 107 (2)
Carcinoma, NOS 1664 (9) 599 (9)
Other carcinoma 3326 (18) 1713 (25)
Treatment modality
Surgery resection 2360 (13) 859 (13) < 0.0001
RT 3970 (22) 1078 (16)
CT 1974 (11) 597 (9)
ST 4316 (24) 2085 (30)
Other complex therapy 40 (< 1) 23 (< 1)
Unknown therapy 5396 (30) 2212 (32)
Abbreviations: S. D., standard deviation.
a May not total 100% due to rounding.
SQCC: squamous cell carcinoma; SCC: small cell carcinoma; LCC: 
large cell carcinoma.
NOS: not otherwise specified.
RT: radiation therapy; CT: chemotherapy; ST: supportive care 
therapy.
Table 2: Association between the prognostic characteristics and 
5-year survival rate in lung cancer subjects
Characteristics Lung cancer death (%)
Males
(N = 12658)
Females
(N = 4571)
p Valuea
All subjects 21.3 23.6 < 0.0001
Period of diagnosis (years)
1987–1990 23.6 24.1 0.3917
1991–1994 19.7 23.2 < 0.0001
p Valuea < 0.0001 0.6865
Diagnostic age (years)
<= 39 30.9 34.5 0.5380
40–49 27.0 25.0 0.7519
50–59 22.8 22.4 0.2629
60–69 21.3 22.9 0.1300
>= 70 20.1 23.3 0.0011
p Valuea < 0.0001 < 0.0001
Residence area
Aboriginal community 29.6 17.3 0.1060
Hakka community 21.7 21.8 0.5235
Hokkien community 21.5 23.8 < 0.001
p Valuea 0.0578 0.2972
Histological types
SQCC 21.5 22.5 0.9190
Adenocarcinoma 18.8 19.5 0.0073
SCC 14.2 15.9 0.1058
LCC 17.8 18.0 0.7648
Carcinoma, NOS 18.2 18.8 0.0534
Other carcinoma 34.2 38.1 0.0012
p Valuea < 0.0001 < 0.0001
Treatment modality
Surgery resection 37.4 42.3 0.0001
RT 15.3 14.5 0.4353
CT 15.3 15.8 0.2509
ST 23.3 24.7 0.0094
Other complex therapy 18.4 13.7 0.5387
Unknown therapy 20.2 22.3 0.0087
p Valuea < 0.0001 < 0.0001
SQCC: squamous cell carcinoma; SCC: small cell carcinoma; LCC: 
large cell carcinoma. NOS: not otherwise specified. RT: radiation 
therapy; CT: chemotherapy; ST: supportive-care therapy. a Log-rank 
testBMC Cancer 2008, 8:324 http://www.biomedcentral.com/1471-2407/8/324
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Survival of males and females associated with death from 
lung cancer (Table 2)
During our follow-up period, total of 17,229 (69%) sub-
jects died from lung cancer. The observed 5-year rate of
survival for lung cancer death was 21.9% (21.3% for
males, 23.6% for females), and 5-year relative survival
was 32.4% (31.4% for males, 35.1% for females). Median
survival was 204.5 days for males and 213.5 days for
females. Fig. 1 denotes males having significantly lower
survival curve than females.
For males, a significantly reduced survival rate was
observed in 1991–1994 than 1987–1990. And in the
period 1991–1994, the 5-year survival rates of females sig-
nificantly higher than males. In terms of both genders, the
5-year survival rates were significantly higher in the
younger diagnostic age groups than older groups. For his-
tological diagnosis, males had a significantly lower sur-
vival estimate for adenocarcinoma than females, and
subjects with SCC have the lowest survival rates (14.2%
for males and 15.9% for females). When comparing treat-
ment modalities, the highest 5-year survival rates were
37.4% in males and 42.3% in females, for surgical resec-
tion alone. Surgery alone, ST alone and unknown therapy
showed females had significantly higher survival rates
than males.
Contribution to prognostic characteristics for lung cancer 
death by each gender (Table 3)
Diagnostic period was a significant predictor of lung can-
cer mortality in males, most evident in the declining sur-
vival trend in 1991–1994. For subjects aged 50–59 years,
60–69 years and over 70 years, they were at significantly
higher risk of dying than those aged 39 years or younger.
For the residence area, males from the Taiwanese aborigi-
nal community have significantly lowest risk of mortality
(HR= 0.85) than the Hokkien community. For the histo-
logical types, males with LCC (HR = 1.38) have signifi-
cantly highest risk of death, than SQCC, followed by SCC
(HR = 1.25), adenocarcinoma (HR = 1.16), and carci-
noma-NOS (HR = 1.16). The risk of death was signifi-
cantly lower for other carcinoma (HR = 0.78 and 0.66 for
males and females, respectively) than for SQCC. Thera-
peutic modalities were also significant predictors of sur-
vival for both genders. There was a significant
improvement in prognosis for subjects treated by surgical
resection alone (HR = 0.60 for males and 0.49 for
females) than CT alone. But males who received ST, RT
and unknown therapy have a significant deleterious effect
(HR = 1.17, 1.11 and 1.11, respectively).
Table 3: Multivariate proportional hazard ratio for lung cancer 
death by gender
Characteristics Lung cancer death (N = 17,229)
Males Females
HR (95% CI) HR (95% CI)
Period of diagnosis (years)
1987–1990 1.00 - 1.00 -
1991–1994 1.13 (1.09–1.18)* 1.03 (0.97–1.10)
Diagnostic age (years)
<= 39 1.00 - 1.00 -
40–49 1.07 (0.93–1.25) 1.17 (1.00–1.37)
50–59 1.25 (1.10–1.42)* 1.24 (1.07–1.43)*
60–69 1.31 (1.15–1.48)* 1.30 (1.13–1.50)*
>= 70 1.43 (1.26–1.62)* 1.37 (1.19–1.58)*
Resident area
Hokkien community 1.00 - 1.00 -
Aboriginal community 0.85 (0.75–0.96)* 1.13 (0.92–1.40)
Hakka community 1.00 (0.94–1.07) 1.02 (0.91–1.14)
Histological type
SQCC 1.00 - 1.00 -
Adenocarcinoma 1.16 (1.11–1.21)* 1.06 (0.98–1.16)
SCC 1.25 (1.17–1.33)* 1.07 (0.91–1.25)
LCC 1.38 (1.21–1.57)* 1.24 (0.98–1.56)
Carcinoma, NOS 1.16 (1.09–1.24)* 1.02 (0.90–1.15)
Other carcinoma 0.78 (0.73–0.82)* 0.66 (0.60–0.73)*
Treatment modality
CT 1.00 - 1.00 -
Surgery resection 0.60 (0.56–0.65)* 0.49 (0.43–0.56)*
RT 1.11 (1.04–1.19)* 1.07 (0.95–1.20)
ST 1.17 (1.10–1.26)* 1.10 (0.98–1.23)
Other complex therapy 1.43 (1.00–2.05) 1.20 (0.75–1.93)
Unknown therapy 1.11 (1.04–1.18)* 1.02 (0.92–1.14)
SQCC: squamous cell carcinoma; SCC: small cell carcinoma; LCC: 
large cell carcinoma. NOS: not otherwise specified. RT: radiation 
therapy; CT: chemotherapy; ST: supportive care therapy. HR: hazard 
ratio; CI: confidence interval. * Statistical significance (p < 0.05).
Survival curves for gender according to lung cancer death (N  = 17229, p < 0.0001) as the endpoints Figure 1
Survival curves for gender according to lung cancer 
death (N = 17229, p < 0.0001) as the endpoints.
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Effects of the covariables on hazard ratio for lung cancer 
death by gender (Table 4)
The crude hazard ratio for males was 1.09 (95% CI:
1.05–1.12) for lung cancer death. After adjusted for all
prognostic factors, males have significantly higher risk of
death than females (HR = 1.07).
Discussion
The five-year survival rate of lung cancer patients in Tai-
wan was poorer than other cancers [15]. European Union
study [16] and United States study [17] have similarly
shown no improvements in prognosis for lung cancer
patients in the two decades prior death. Our Kaplan-Meier
analysis showed that 5-year survival rate of lung cancer
death was higher than in Western population, possibly
because the 5-year survival rate of lung cancer death has
eliminated other competing causes of death [3,8,17]. Past
studies have focused on differences in incidence and his-
tological types of lung cancer by gender [16,18,19].
Present study showed survival and prognostic factors of
lung cancer by gender from lung cancer databases, and
lung cancer death as outcome used in effort to clear arbi-
trary effect of death from other causes.
Gender differences in the survival of subjects diagnosed 
with lung cancer
Our findings showed the long-term survival rate was sig-
nificantly better for females, and the average diagnostic
age was significantly higher for males, as consistent with
other publications on gender and survival of lung cancer
patients [2,3,7,20]. Our large lung cancer database con-
firmed gender to be an independent predictor of lung can-
cer prognosis by the multivariate Cox analysis, moreover
males diagnosed with lung cancer had a risk 1.07 times
higher than females.
Prognostic factors in the survival of subjects diagnosed 
with lung cancer
The proportion of lung cancer subjects in 1991–1994 was
significantly higher than 1987–1990, during which lung
cancer posed diagnostic and therapeutic challenges, with
extremely poor prognosis. Our finding showed, for males,
the mortality to be significantly higher and survival rates
to be significantly lower in the periods 1991–1994 than
1987–1990. Possibly, the declining survival rates reflected
no improvements to early cancer detection or treatment
efficacy, and warrants further attention.
In review of diagnostic age on lung cancer death, increas-
ing age, especially older than 70 years, remained signifi-
cant risk factor in both genders. Other reports also noted
increasing age possessed an adverse effect on survival for
lung cancer patients [4,5,16,21]. There may be poorer tol-
erance to treatment, and health conditions in older
patients. Differing opinions exist regarding relationship
between diagnostic age and survival rate in lung cancer
patients [22,23].
For histological distribution, SQCC has frequently
occurred in males and adenocarcinoma in females. The
lowest 5-year survival rate was seen in both genders with
SCC. Similar evidence has been shown by studies con-
ducted in Norway [3] and France [24]. After adjusted for
diagnostic period, diagnostic age, resident area, and treat-
ment modality, males with LCC had a significantly high-
est risk in terms of mortality. The impact of histological
diagnosis was notable in males with adenocarcinoma,
SCC and LCC, have significantly poorer prognosis com-
pared to SQCC type. Males also have significantly lower
survival estimate of adenocarcinoma than females. A
switch in occurrence of SQCC in Taiwanese men to aden-
ocarcinoma, SCC and LCC was observed in 1987 to 2003
[11]. These results could partially explain for the poor
prognosis in males.
Currently, complete surgical resection offer effective ther-
apy for lung cancer patients [6,10]. This study showed sur-
gical resection to markedly improve outcome for both
genders, and survival by surgical resection was signifi-
cantly better for females. Previous studies also noted
females to have better postoperative survival and progno-
sis [2,3,25,26]. Differences in aspects of medical interven-
Table 4: Crude and adjusted hazard ratio for males versus females according to lung cancer death
Lung cancer death
(N = 17,229)
M: FaHR (95% CI)
Crude hazard ratios 1.09 (1.05–1.12)*
Adjusted hazard ratios
Adjusted for the period of diagnosis (years) 1.09 (1.05–1.13)*
Above plus diagnostic age, resident area 1.06 (1.03–1.10)*
Above plus morphological type, treatment modality 1.07 (1.03–1.11)*
Abbreviations: HR: hazard ratio; CI = confidence interval.
aM:F: male -to- female ratio.
* Statistical significance (p < 0.0001).BMC Cancer 2008, 8:324 http://www.biomedcentral.com/1471-2407/8/324
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tion may have accounted for gender disparity in terms of
survival rates. We showed surgical resection to be protec-
tive. As in another study, surgical resection was also bene-
ficial to survival [4,6,10,16].
Subjects treated with ST alone or did not receive any spe-
cific treatment for lung cancer have unfavorable prognosis
[4,9,16]. In this study, 5-year survival rate of ST alone was
better than RT, CT in both genders. But after adjusted for
other prognostic factors, 5-year survival rate of ST therapy
have markedly deleterious effect. Except for unknown
therapy, females were more likely to choose ST therapy
than males. From clinical expertise, physicians specialized
in chest medicine considered this possibly due to females
fearing the adverse effects (such as lose hair, vomit, etc) of
RT, CT therapy. Females spent more time accessing the
health care system, the disease was therefore found at an
earlier diagnostic age than males (17% for females and
7% for males are under 50 years of age). Johnston et al.
showed hormonal role may also influence survival rates
in terms of gender where androgens may have stimulatory
effect on lung cancer growth [20].
Lung cancer survival has strongly dependent upon the
staging [2,3,6,16]. This was a limitation in this study, as
data pertained to exact staging was unavailable on the
TCR. Zhang et al. has recommended surgery for stage I, II
and stage IIIa in non-SCC and stage I, II in SCC [6]. Data
on early clinical staging of cancer could be available for
surgical resection alone. But treatment by CT alone, RT, ST
alone meant diagnoses were made at advanced stages of
the disease. Several researchers obtained similar results
[2,16]. As result, we evaluated surgical effects on survival
instead of clinical stages. In our analytical procedure, sub-
jects were categorized into surgery and non-surgery ther-
apy, and survival rates of these two groups compared.
Results indicated the survival of surgery group to be signif-
icantly higher than the non-surgery group (data not
shown). Except for SCC patients, the 5-year survival of his-
tological types showed significant differences between
patients with or without surgery (Table 5). Surgical resec-
tion has markedly increased 5-year survival, decreased the
risk of death of LCC patients, but no improvement to the
survival of SCC patients. As staging is unavailable to TCR,
individual subjects' therapeutic choices could be treated
as a clinical reference.
In addition to the factors aforementioned, cigarette smok-
ing has been well-known risk factor for lung cancer
patients to dramatically decrease survival rates
[5,8,24,27]. But information on cigarette smoking was
unavailable on the TCR until 2007 in Taiwan. The causal
factors of lung cancer between males and females have
been heterogeneous [18]. Statistics showed 86% of male
lung cancer and 9–10% of female lung cancer as having
social history of cigarette smoking [28], could explain the
Table 5: Five-year survival rates and multivariate proportional hazard ratio of lung cancer death by surgical status
Characteristics Lung cancer death
(N = 17,229)
Surgery Non-surgery
Survival rates (%) Survival rates (%) p Valuea
HR (95% CI) HR (95% CI)
All subjects 38.8 19.3 < 0.0001
Histological types
SQCC 41.6 16.9 < 0.0001
1.00 - 1.00 -
Adenocarcinoma 36.5 14.7 < 0.0001
1.14 (1.03–1.26)* 1.14 (1.09–1.19)*
SCC 17.1 14.3 0.5716
2.49 (2.05–3.03)* 1.13 (1.07–1.20)*
LCC 43.7 11.9 < 0.0001
1.01 (0.74–1.38) 1.42 (1.26–1.61)*
Carcinoma, NOS 31.7 17.5 0.0001
1.53 (1.24–1.89)* 1.12 (1.05–1.18)*
Other carcinoma 65.0 34.1 < 0.0001
0.59 (0.45–0.78)* 0.77 (0.74–0.81)*
SQCC: squamous cell carcinoma; SCC: small cell carcinoma; LCC: large cell carcinoma.
NOS: not otherwise specified.
RT: radiation therapy; CT: chemotherapy; ST: supportive care therapy. aLog-rank test. HR: hazard ratio; CI: confidence interval. * Statistical 
significance (p < 0.05).BMC Cancer 2008, 8:324 http://www.biomedcentral.com/1471-2407/8/324
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poorer prognosis in Taiwanese males. Cooking oil fume
and environmental tobacco smoke accounted for the larg-
est proportion of attributable risk of lung cancer in
women [18,28]. Taiwanese women have relatively high
lung cancer incidence in spite very few smokers. However,
smoking behavior could not fully explain the differences
in epidemiological characteristics of lung cancer between
males and females in Taiwan. Many reports from North
America have similar smoking rates in gender, still found
females to have better survival than males [17,20,29].
Gender is an independent factor to dominate the survival
of lung cancer.
Conclusion
This study analysed the long-term survival of lung cancer
patients from the population data in the TCR, and identi-
fied gender as an important and independent prognostic
factor for lung cancer death patients. Clinical characteris-
tics (i.e. diagnostic period, diagnostic age, histological
type, treatment modality) have important roles in lung
cancer survival.
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